Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1083/jcb.202006005 http://scihub22266oqcxt.onion/10.1083/jcb.202006005 32725137!7480111!32725137     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32725137.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       J+Cell+Biol 2020 ; 219 (9): ä Nephropedia Template TP {{tp|p=32725137|t=2020. Role of the early secretory pathway in SARS-CoV-2 infection |pdf=|usr=}}{{32725137}} gab.com Text Role of the early secretory pathway in SARS-CoV-2 infection JO: J Cell Biol http://www.kidney.de/pget.php?&tw=1&pmid=32725137 #FOAvip Similar to other RNA viruses, SARS-CoV-2 must (1) enter a target/host cell, (2) reprogram it to ensure its replication, (3) exit the host cell, and (4) repeat this cycle for exponential growth. During the exit step, the virus hijacks the sophisticated machineries that host cells employ to correctly fold, assemble, and transport proteins along the exocytic pathway. Therefore, secretory pathway-mediated assemblage and excretion of infective particles represent appealing targets to reduce the efficacy of virus biogenesis, if not to block it completely. Here, we analyze and discuss the contribution of the molecular machines operating in the early secretory pathway in the biogenesis of SARS-CoV-2 and their relevance for potential antiviral targeting. The fact that these molecular machines are conserved throughout evolution, together with the redundancy and tissue specificity of their components, provides opportunities in the search for unique proteins essential for SARS-CoV-2 biology that could also be targeted with therapeutic objectives. Finally, we provide an overview of recent evidence implicating proteins of the early secretory pathway as potential antiviral targets with effective therapeutic applications. Twit Text FOAVip Role of the early secretory pathway in SARS-CoV-2 infection ????J Cell Biol http://www.kidney.de/pget.php?&tw=1&pmid=32725137 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32725137 #FOAvip English Wikipedia <ref>{{Cite pmid|32725137}}</ref> Role of the early secretory pathway in SARS-CoV-2 infection #MMPMID32725137 Sicari D; Chatziioannou A; Koutsandreas T; Sitia R; Chevet E J Cell Biol 2020[Sep]; 219 (9): ä PMID32725137show ga Similar to other RNA viruses, SARS-CoV-2 must (1) enter a target/host cell, (2) reprogram it to ensure its replication, (3) exit the host cell, and (4) repeat this cycle for exponential growth. During the exit step, the virus hijacks the sophisticated machineries that host cells employ to correctly fold, assemble, and transport proteins along the exocytic pathway. Therefore, secretory pathway-mediated assemblage and excretion of infective particles represent appealing targets to reduce the efficacy of virus biogenesis, if not to block it completely. Here, we analyze and discuss the contribution of the molecular machines operating in the early secretory pathway in the biogenesis of SARS-CoV-2 and their relevance for potential antiviral targeting. The fact that these molecular machines are conserved throughout evolution, together with the redundancy and tissue specificity of their components, provides opportunities in the search for unique proteins essential for SARS-CoV-2 biology that could also be targeted with therapeutic objectives. Finally, we provide an overview of recent evidence implicating proteins of the early secretory pathway as potential antiviral targets with effective therapeutic applications. |Antiviral Agents/therapeutic use[MESH] |Betacoronavirus/drug effects/*pathogenicity[MESH] |COVID-19[MESH] |Coronavirus Infections/drug therapy/*virology[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/drug therapy/*virology[MESH] |SARS-CoV-2[MESH] |Secretory Pathway/drug effects/*physiology[MESH]Role of the early secretory pathway in SARS-CoV-2 infection (epmc).pdf DeepDyve Pubget Overpricing